Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Roger Mulet-Lazaro, Aniko Sijs-Szabó, Remco Hoogenboezem, Stanley Van Herk, Patricia G. Hoogeveen, Francois Kavelaars, Anita Schelen, Willemijn van den Ancker, Arjan A. van de Loosdrecht, Berna Beverloo, Vincent H.J. Van Der Velden, Jan J. Cornelissen, Peter J. M. Valk, Anita W. Rijneveld, Mathijs Arnoud Sanders

Blood (2024) 144 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2024-209773

Published: 2024

Journal Articles

ABL-Class Fusion Gene Induced Pediatric CML Presenting As ALL

Peter M. Hoogerbrugge, Maaike Luesink, Judith M. Boer, Inge Van Outersterp, Edwin Sonneveld, Anja De Jong, Stefan Nierkens, Vincent H.J. Van Der Velden, Arjan Buijs, Monique L. den Boer

Blood (2024) 144 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2024-203064

Published: 2024

Journal Articles

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. Van Der Velden, H. Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Elena Zamagni, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2023-178533

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. van der Velden, Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 10177–10179.

https://doi.org/10.1182/blood-2022-160004

Published: 2022

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

A Novel Germline PAX5 Single Exon Deletion in a Paediatric Patient with B-Cell Leukaemia

Nienke van Engelen, Merel A. Roest, Freerk van Dijk, Edwin Sonneveld, Reno Bladergroen, Simon van Reijmersdal, Vincent H.J. van der Velden, Patricia G. Hoogeveen, W.A. Kors, Esme Waanders, Roland P. Kuiper, Marjolijn C.J. Jongmans

Blood (2022) 140 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2022-159959

Published: 2022

Journal Articles

Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses

Cédric G van der Ham, Stefan H Lelieveld, Željko Antic, Marley Yeong, Lianne C Suurenbroek, Dorette S van Ingen Schenau, Lennart A. Kester, Liset Westera, Edwin Sonneveld, Peter M. Hoogerbrugge, Vincent H.J. van der Velden, Frank N van Leeuwen, Roland P. Kuiper

Blood (2022) 140 (Supplement 1): 3463–3464.

https://doi.org/10.1182/blood-2022-159410

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 3518–3520.

https://doi.org/10.1182/blood-2022-166043

Published: 2022

Journal Articles

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Blood (2022) 140 (Supplement 1): 8890–8892.

https://doi.org/10.1182/blood-2022-163055

Published: 2022

Journal Articles

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Cathelijne Fokkema, Madelon M.E. de Jong, Sabrin Tahri, Davine Hofste Op Bruinink, Zoltan Kellermayer, Chelsea den Hollander, Michael Vermeulen, Natalie Papazian, Mark van Duin, Remco Hoogenboezem, Michiel J.W. Wevers, Vincent H.J. van der Velden, Mathijs A. Sanders, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9917–9918.

https://doi.org/10.1182/blood-2022-166162

Published: 2022

Journal Articles

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Rob Pieters, Hester A. De Groot-Kruseman, Femke Verwer, Merian van Overveld, Edwin Sonneveld, Marta Fiocco, Vincent H.J. van der Velden, Berna Beverloo, Marc Bierings, Valerie De Haas, Peter M. Hoogerbrugge, Inge M. Van Der Sluis, Wim J.E. Tissing, Margreet Veening, Judith M. Boer, Monique L. den Boer

Blood (2022) 140 (Supplement 1): 519–520.

https://doi.org/10.1182/blood-2022-165931

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sabrin Tahri, Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Kazem Nasserinejad, Elona Saraci, Mattia D'Agostino, Francesca Gay, Vincent H.J. van der Velden, Niels WCJ Van De Donk, Annemiek Broijl, Pieter Sonneveld, Sonja Zweegman, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9982–9984.

https://doi.org/10.1182/blood-2022-164812

Published: 2022

Journal Articles

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Britt M T Vervoort, Miriam Butler, Dorette van Ingen Schenau, Vincent H.J. van der Velden, Beat Bornhauser, Jean-Pierre Bourquin, Laurens T van der Meer, Frank N van Leeuwen

Blood (2022) 140 (Supplement 1): 3465–3466.

https://doi.org/10.1182/blood-2022-162246

Published: 2022

Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Blood (2021) 138 (Supplement 1): 82.

https://doi.org/10.1182/blood-2021-147897

Published: 2021

Journal Articles

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

Marie-Helene Delfau, Elizabeth A. Macintyre, Mary B. Callanan, Christiane Pott, Vincent H.J. Van Der Velden, Christa Homburg, Ramon Garcia-Sanz, Paula Gameiro, Maria Gomes Da Silva, Wolfram Klapper, Lucie Oberic, Pierre Feugier, Violaine Safar, Olivier Casasnovas, Martin H. Dreyling, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 40.

https://doi.org/10.1182/blood-2021-145288

Published: 2021

Journal Articles

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2021) 138 (Supplement 1): 2383.

https://doi.org/10.1182/blood-2021-145058

Published: 2021

NARROW

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

ABL-Class Fusion Gene Induced Pediatric CML Presenting As ALL

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

A Novel Germline PAX5 Single Exon Deletion in a Paediatric Patient with B-Cell Leukaemia

Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only